Endocrinology   

Would you recommend aiming for the postmenopausal range as per the lab reference range or do you have a specific goal?

Or other therapy - e.g., tolvaptan? Free water restriction may hinder QOL. Salt tablets may raise levels more quickly but have risks of edema and hype...

Only the mCRPC population was included in the Fizazi et al. study, but the FDA approval is for prevention of skeletal related events from any solid tu...

Would you consider it for a patient with good PS but with limited metastatic disease? What dose fractionation would you prefer?

If so, what do you typically prescribe?

With studies showing non inferiority to zoledronic acid q 3 months in support of bone metastatic disease, would you consider extrapolating this data a...

If so, how often do you check these labs?

Do you look into their stage/risk to decide? Since patients can experience bone loss after stopping denosumab, how do you plan to discontinue?

Would you consider omitting treatment if small tumor and early stage? Or would you use tamoxifen?

Which agents would you select and for how long would you treat them?

For pts w/ eGFR between 30-60

Does the degree of resectability affect your management?

Recommendations in guidelines are discordant (ASCO vs NCCN vs UptoDate).

Is there concern for impaired healing? Do you pause therapy and for how long?

Should it be started at the initial diagnosis of bone mets?

What factors if any would influence your decision and what would your approach be? 

Do you extrapolate the results of OPTIMIZE-2 and CALGB 70604 showing that an every 12 week dosing of zolendronic acid is noninferior to ever...

If a patient had a recurrence that was pathologically proven despite negative idodine scans, what imaging scans would you follow up with for surveilla...